QT Sense B.V.

QT Sense focuses on advancing quantum sensing technology, particularly in biomedical applications, by creating innovative products that enhance the understanding of cellular dynamics. QT Sense was founded in 2024 in Groningen, Netherlands, specializing in quantum sensing technology. The company was established to develop products for real-time monitoring of oxidative stress at the cellular level. The founder has a history of entrepreneurial ventures, although specific details of previous companies are not available.

In January 2026, QT Sense B. V. raised EUR 4 million in seed and grant funding led by Cottonwood Technology Fund, with participation from QDNL Participations and Quantum Delta NL. QT Sense specializes in advanced quantum sensing technology, with its flagship product, the Quantum Nuova.

This device is designed for real-time monitoring of oxidative stress at the cellular level, utilizing diamond-based magnetometry to measure free radicals with nanoscale precision. The technology has been particularly useful in biomedical research, addressing critical health conditions linked to oxidative stress, such as cancer, male fertility, and arthritis. Customers include academic research institutions and medical facilities, primarily in North America and Europe, where the product has been implemented in studies to assess drug efficacy, investigate cellular responses, and differentiate between types of arthritis. The Quantum Nuova offers a non-invasive approach, enabling researchers to gain insights into cellular dynamics without compromising cell viability, thus facilitating advancements in various therapeutic areas.

The revenue model for QT Sense is structured around direct sales of the Quantum Nuova and its optional components, which enhance the core system’s capabilities for specific applications. Clients typically engage in purchasing the device outright and may also take advantage of leasing options, allowing for a minimum 12-month commitment. Transactions are primarily conducted in a B2B environment, targeting universities, research centers, and pharmaceutical companies. The pricing structure includes the base unit of the Quantum Nuova, with further customization available through optional accessories and consumables, which are essential for conducting experiments.

This transactional framework supports a steady revenue stream, allowing QT Sense to expand its customer base while contributing to ongoing research and development efforts in the field of quantum sensing and biomedical applications. The company will use the funding to transition Quantum Nuova from a prototype to a deployable platform by improving hardware robustness, throughput, analytics, and supporting oncology research and real-world deployments.